Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Dermata TherapeuticsDRMA +0.39%26 3-Year EBITDA Growth Rate is 83.70% as of Jun. 2026, which is 71% above its 10-year median of 48.85. GuruFocus rates DRMA with a GF Score™ of 26/100. The stock has 2 warning signs investors should review. Among 1,127 Biotechnology companies, Dermata Therapeutics ranks better than 97.16% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 83.70% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 65.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 7 years, the highest 3-Year average EBITDA Per Share Growth Rate of Dermata Therapeutics was 83.70% per year. The lowest was -9.10% per year. And the median was 48.85% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Dermata Therapeutics 3-Year EBITDA Growth Rate Related Terms
DRMA vs CLGN, RVPH, ADTX: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Dermata Therapeutics's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dermata Therapeutics 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Dermata Therapeutics's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Dermata Therapeutics's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 83.70% mean?
Dermata Therapeutics (DRMA) has a 3-Year EBITDA Growth Rate of 83.70% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Dermata Therapeutics and its competitors. This is 71% above median its historical median of 48.85. According to the industry distribution chart, Dermata Therapeutics ranks #32 out of 1127 companies in the Biotechnology industry, placing it in the top 2.8%.
Is Dermata Therapeutics' 3-Year EBITDA Growth Rate too high?
Dermata Therapeutics' current 3-Year EBITDA Growth Rate of 83.70% is 71% above median its 10-year median of 48.85. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.90. Dermata Therapeutics' value of 83.70% is 461.7% above this industry median. Based on the distribution chart, Dermata Therapeutics ranks #32 out of 1127 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Dermata Therapeutics has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Dermata Therapeutics' 3-Year EBITDA Growth Rate compare to CLGN and RVPH?
According to the Biotechnology industry distribution chart, Dermata Therapeutics ranks #32 out of 1127 companies for 3-Year EBITDA Growth Rate. This places Dermata Therapeutics in the top 3% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 14.90. Dermata Therapeutics' value of 83.70% is 461.7% above this benchmark. While the company's 10-year median is 48.85 vs. the industry median of 14.90, Dermata Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.90, based on 1,127 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Dermata Therapeutics's current 3-Year EBITDA Growth Rate of 83.70% is 461.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Dermata Therapeutics and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Dermata Therapeutics's current 3-Year EBITDA Growth Rate is 83.70%, which is 71% above median its own 10-year median of 48.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dermata Therapeutics stock overvalued right now?
Dermata Therapeutics (DRMA) has a current 3-Year EBITDA Growth Rate of 83.70%. The current 3-Year EBITDA Growth Rate is 83.70%, which is 71% above median its 10-year median of 48.85 and 461.7% above the Biotechnology industry median of 14.90. Dermata Therapeutics' overall GF Score™ is 26/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Dermata Therapeutics (DRMA), the current 3-Year EBITDA Growth Rate is 83.70% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Dermata Therapeutics Inc develops and commercializes dermatology products for the treatment of common skin conditions. It focuses on leveraging prior clinical and technical expertise to develop OTC treatments for conditions such as acne, psoriasis, rosacea, and seborrheic dermatitis. The company is currently developing a once-weekly acne treatment system that utilizes an active ingredient from the OTC monograph in combination with the company's Spongilla technology. It intends to apply its Spongilla technology platform across a range of dermatologic and aesthetic skin applications, including intradermal delivery of botulinum toxin. The company's operates in one segment, which is the business of developing, branding, marketing, and commercializing direct to consumer skincare products.
26GF Score
Get the complete analysis for DRMA
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DRMA has been successfully added to your 
